These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Biomarkers of tumor-reactive CD4 Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331 [TBL] [Abstract][Full Text] [Related]
10. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029 [TBL] [Abstract][Full Text] [Related]
11. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer. Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000 [TBL] [Abstract][Full Text] [Related]
12. Bystander CD4 Li S; Zhuang S; Heit A; Koo SL; Tan AC; Chow IT; Kwok WW; Tan IB; Tan DSW; Simoni Y; Newell EW Oncoimmunology; 2022; 11(1):2012961. PubMed ID: 36524209 [TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. Balança CC; Salvioni A; Scarlata CM; Michelas M; Martinez-Gomez C; Gomez-Roca C; Sarradin V; Tosolini M; Valle C; Pont F; Ferron G; Gladieff L; Vergez S; Dupret-Bories A; Mery E; Rochaix P; Fournié JJ; Delord JP; Devaud C; Martinez A; Ayyoub M JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33332284 [TBL] [Abstract][Full Text] [Related]
14. Reversal of the CD8 Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C Front Immunol; 2021; 12():687296. PubMed ID: 34177939 [TBL] [Abstract][Full Text] [Related]
15. Enrichment of Inflammatory IL-17 and TNF-α Secreting CD4(+) T Cells within Colorectal Tumors despite the Presence of Elevated CD39(+) T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1. Dunne MR; Ryan C; Nolan B; Tosetto M; Geraghty R; Winter DC; O'Connell PR; Hyland JM; Doherty GA; Sheahan K; Ryan EJ; Fletcher JM Front Oncol; 2016; 6():50. PubMed ID: 27014625 [TBL] [Abstract][Full Text] [Related]
16. Location of CD39 Koppensteiner L; Mathieson L; Pattle S; Dorward DA; O'Connor R; Akram AR J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648263 [TBL] [Abstract][Full Text] [Related]
17. Circulating mycobacterial-reactive CD4+ T cells with an immunosuppressive phenotype are higher in active tuberculosis than latent tuberculosis infection. Kim K; Perera R; Tan DB; Fernandez S; Seddiki N; Waring J; French MA Tuberculosis (Edinb); 2014 Sep; 94(5):494-501. PubMed ID: 25095750 [TBL] [Abstract][Full Text] [Related]
18. CD39 Identifies the CD4 Kortekaas KE; Santegoets SJ; Sturm G; Ehsan I; van Egmond SL; Finotello F; Trajanoski Z; Welters MJP; van Poelgeest MIE; van der Burg SH Cancer Immunol Res; 2020 Oct; 8(10):1311-1321. PubMed ID: 32759363 [TBL] [Abstract][Full Text] [Related]
19. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma. Brauneck F; Weimer P; Schulze Zur Wiesch J; Weisel K; Leypoldt L; Vohwinkel G; Fritzsche B; Bokemeyer C; Wellbrock J; Fiedler W Front Med (Lausanne); 2021; 8():763773. PubMed ID: 34820398 [No Abstract] [Full Text] [Related]
20. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Schuler PJ; Schilling B; Harasymczuk M; Hoffmann TK; Johnson J; Lang S; Whiteside TL Eur J Immunol; 2012 Jul; 42(7):1876-85. PubMed ID: 22585562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]